Table 1.
Baseline Demographics and Clinicopathologic Variables of Patients with <2 cm Low/Intermediate Grade,Non-functional, Pancreatic Neuroendocrine Tumors (PNETs) from the US-NETSG Database who underwent Curative-intent Resection from 2000–2016 (n=309).
| Baseline Variables | n (%) |
|---|---|
| Age (y), mean ± SD | 58 ± 12 |
|
| |
| Male, n (%) | 147 (48) |
|
| |
| BMI, mean ± SD | 29 ± 6 |
|
| |
| Comorbidities, n (%)a | |
| 0 | 106 (34) |
| 1 | 91 (29) |
| ≥2 | 108 (35) |
|
| |
| Race, n (%) | |
| White | 231 (76) |
| Black | 32 (11) |
| Other | 40 (13) |
|
| |
| ASA class, n (%) | |
| 1 | 6 (2) |
| 2 | 143 (47) |
| 3 | 151 (50) |
| 4 | 3 |
|
| |
| CgA (ng/L), mean ± SD | 176 ± 332 |
|
| |
| Operative/ Pathologic Data | n (%) |
|
| |
| Tumor Size (cm), mean ± SD | 1.3 ± 0.4 |
|
| |
| Location of Tumor in Pancreas, n (%) | |
| Head/uncinate (Proximal) | 77 (25) |
| Neck/body/tail (Distal) | 232 (75) |
|
| |
| OperativeTechnique, n (%) | |
| Open | 198 (64) |
| Laparoscopic | 70 (23) |
| Other | 31 (13) |
|
| |
| Type of Resection, n (%) | |
| Enucleation | 28 (9) |
| Classic pancreatoduodenectomy | 25 (8) |
| Pylorus preserving pancreatoduodenectomy | 36 (12) |
| Central pancreatectomy | 22 (7) |
| Distal pancreatectomy | 195 (63) |
| Total pancreatectomy | 3 (1) |
|
| |
| Tumor Differentiation, n (%) | |
| Well | 258 (93) |
| Moderate | 21 (8) |
|
| |
| Ki-67 Index, n (%) | |
| < 3% | 177 (77) |
| 3–20% | 52 (23) |
|
| |
| Lymph Node-Positive, n (%) | 22 (9) |
|
| |
| Lymph Node Yield, median (IQR) | 8 (3–13) |
| *ELSEVIER SEE BELOW Pancreatoduodenectomy | 11 (7–17) |
| Distal Pancreatectomy | 8 (4–12) |
| Enucleation/Central pancreatectomy | 1 (1–2) |
|
| |
| Post-operative Data | n (%) |
|
| |
| Clavien-Dindo Classification, n (%)b | |
| I | 48 (26) |
| II | 67 (37) |
| IIIa | 43 (23) |
| IIIb | 11 (6) |
| IVa | 11 (6) |
| IVb | 3 (2) |
|
| |
| Disease Recurrence | 13 (4) |
|
| |
| Region of Recurrence | |
| Locoregional | 6 (46) |
| Locoregional + Distant | 0 (0) |
| Distant | 7 (54) |
|
| |
| Deaths | 11 (4) |
|
| |
| Time to Death | |
| <30 days | 0 (0) |
| 31–60 days | 0 (0) |
| 61–90 days | 0 (0) |
| ≥90 days | 11 (100) |
Abbreviations: SD, standard deviation; BMI, body mass index; ASA, American Society of Anesthesiologists; CgA, chromogranin A; IQR, interquartile range;
Comorbidities are defined as any concurrent medical condition, including but not limited to, heart disease, chronic pulmonary disease, diabetes, renal disease, and liver disease as per the American College of Surgeons National Surgical Quality Improvement Program Risk Calculator.
Clavien-Dindo is a grading scale for ranking the severity of post-operative complications ranging from I-V, where I represents the lowest acuity complication (one not requiring pharmacological treatment or surgical, endoscopic, or radiologic intervention), and V represents death.
ELSEVIER THE THREE OPERATIVE PROCEDURES ARE IN A UNIQUE GROUP OF PATIENTS THAT NEEDS TOP BE DEFINED IN THE TABLE – I THINK THESE REPRESENT THE PATIENTS WITH LYMPH NODE-POSTITIVE DISEASE THIS NEEDS TO BE SPECIFIED BY THE AUTHORS